Evidence map›Paper›PMID 30521599›Full record

ArticlePloS one2018

Global analysis of erythroid cells redox status reveals the involvement of Prdx1 and Prdx2 in the severity of beta thalassemia.

Karen S Romanello, Karina K L Teixeira, João Pedro M O Silva, Sheila T Nagamatsu, Marcos André C Bezerra, Igor F Domingos, Diego A P Martins, Aderson S Araujo, Carolina Lanaro, Carlos A Breyer and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. [Regulation effect of siRNA on β-globin in erythrocytes of hemoglobin H disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021
    Article
  13. Current status of beta-thalassemia and its treatment strategies.Molecular genetics & genomic medicine · 2021
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Karen S RomanelloUniversidade Federal de São Carlos (UFSCar), Departamento de Genética e Evolução, São Carlos, Brazil.
Karina K L TeixeiraUniversidade Federal de São Carlos (UFSCar), Departamento de Genética e Evolução, São Carlos, Brazil.
João Pedro M O SilvaUniversidade Federal de São Carlos (UFSCar), Departamento de Genética e Evolução, São Carlos, Brazil.
Sheila T NagamatsuUniversidade de Campinas (UNICAMP), Departamento de Genética, Evolução e Bioagentes, Campinas, Brazil.
Marcos André C BezerraUniversidade Federal de Pernambuco (UFPE), Departamento de Genética, Pernambuco, Brazil.
Igor F DomingosUniversidade Federal de Pernambuco (UFPE), Departamento de Genética, Pernambuco, Brazil.
Diego A P MartinsUniversidade Federal de Pernambuco (UFPE), Departamento de Genética, Pernambuco, Brazil.
Aderson S AraujoFundação de Hematologia e Hemoterapia do estado de Pernambuco (HEMOPE), Pernambuco, Brazil.
Carolina LanaroHemocentro da Universidade de Campinas (UNICAMP), Campinas, Brazil.
Carlos A BreyerUniversidade Estadual Paulista (UNESP)-Campus Litoral Paulista, São Vicente, Brazil.
Regiane A FerreiraHemocentro da Universidade de Campinas (UNICAMP), Campinas, Brazil.
Carla Franco-PenteadoHemocentro da Universidade de Campinas (UNICAMP), Campinas, Brazil.
Fernando F CostaHemocentro da Universidade de Campinas (UNICAMP), Campinas, Brazil.
Iran MalavaziUniversidade Federal de São Carlos (UFSCar), Departamento de Genética e Evolução, São Carlos, Brazil.ORCID 0000-0002-4526-4961
Luis E S NettoUniversidade de São Paulo (USP), Departamento de Genética, Biologia Evolutiva, São Paulo, Brazil.
Marcos A de OliveiraUniversidade Estadual Paulista (UNESP)-Campus Litoral Paulista, São Vicente, Brazil.
Anderson F CunhaUniversidade Federal de São Carlos (UFSCar), Departamento de Genética e Evolução, São Carlos, Brazil.ORCID 0000-0003-3485-5659
Universidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de São Carlos · BRUniversidade Federal de Pernambuco · BRUniversidade Paulista · BRFundação Hemopa · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-thalassemia is a worldwide distributed monogenic red cell disorder, characterized by an absent or reduced beta globin chain synthesis. The unbalance of alpha-gamma chain and the presence of pathological free iron promote severe oxidative damage, playing crucial a role in erythrocyte hemolysis, exacerbating ineffective erythropoiesis and decreasing the lifespan of red blood cells (RBC). Catalase, glutathione peroxidase and peroxiredoxins act together to protect RBCs from hydrogen peroxide insult. Among them, peroxiredoxins stand out for their overall abundance and reactivity. In RBCs, Prdx2 is the third most abundant protein, although Prdxs 1 and 6 isoforms are also found in lower amounts. Despite the importance of these enzymes, Prdx1 and Prdx2 may have their peroxidase activity inactivated by hyperoxidation at high hydroperoxide concentrations, which also promotes the molecular chaperone activity of these proteins. Some studies have demonstrated the importance of Prdx1 and Prdx2 for the development and maintenance of erythrocytes in hemolytic anemia. Now, we performed a global analysis comparatively evaluating the expression profile of several antioxidant enzymes and their physiological reducing agents in patients with beta thalassemia intermedia (BTI) and healthy individuals. Furthermore, increased levels of ROS were observed not only in RBC, but also in neutrophils and mononuclear cells of BTI patients. The level of transcripts and the protein content of Prx1 were increased in reticulocyte and RBCs of BTI patients and the protein content was also found to be higher when compared to beta thalassemia major (BTM), suggesting that this peroxidase could cooperate with Prx2 in the removal of H2O2. Furthermore, Prdx2 production is highly increased in RBCs of BTM patients that present high amounts of hyperoxidized species. A significant increase in the content of Trx1, Srx1 and Sod1 in RBCs of BTI patients suggested protective roles for these enzymes in BTI patients. Finally, the upregulation of Nrf2 and Keap1 transcription factors found in BTI patients may be involved in the regulation of the antioxidant enzymes analyzed in this work.

Indexed as

AdolescentAdultbeta-ThalassemiaBlotting, WesternChildChild, PreschoolErythrocytesErythroid CellsFemaleHumansLeukocytes, MononuclearMaleMiddle AgedNeutrophilsOxidation-ReductionPeroxiredoxinsPeroxiredoxinsPRDX1 protein, humanPRDX2 protein, humanReactive Oxygen Species

Identifiers

PMID30521599
PMCPMC6283586
OpenAlexW2904424948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.